Particle.news
Download on the App Store

Enlivex Raises $21 Million, Buys 3 Billion RAIN Tokens at a Discount

The move signals a dual-track plan that couples Allocetra’s clinical push with a treasury bet on Rain’s fee-funded token buybacks.

Overview

  • Enlivex closed a $21 million financing from The Lind Partners structured as a convertible note with a fixed $2.69175 per-share conversion price and about $18.7 million in net proceeds.
  • The company exercised an option to purchase roughly 3 billion RAIN tokens for $10 million at $0.0033 per token, which it said was about 62% below the market price.
  • Enlivex extended rights to acquire about 272.1 billion additional RAIN tokens at the same price through December 2027 for long-term flexibility.
  • The board authorized a $20 million share repurchase program with no set end date as part of its broader capital allocation plan.
  • RAIN briefly rose about 7% before settling near $0.0088, and Enlivex shares were little changed in regular trading and up after hours, as investors weighed Rain’s 2.5% trading fee that buys back and burns tokens.